Medicine and Dentistry
Action Study
16%
Adalimumab
16%
Biological Product
24%
Clinical Trial
11%
Cohort Analysis
33%
Dermatosis
10%
Disease
17%
Disease Burden
16%
Disease Duration
8%
Disease Severity
5%
Etretin
9%
Guselkumab
16%
Hidradenitis Suppurativa
100%
Infliximab
16%
Isotretinoin
7%
Kaplan Meier Method
6%
Major Surgery
16%
Patient-Reported Outcome
7%
Proportional Hazards Model
6%
Quality of Life
16%
Retinoid
16%
Survival Rate
6%
Survival Time
10%
Wound Closure
16%
Pharmacology, Toxicology and Pharmaceutical Science
Adalimumab
16%
Biological Product
23%
Cohort Study
34%
Comorbidity
16%
Disease
16%
Disease Duration
8%
Etretin
9%
Guselkumab
16%
Infliximab
16%
Isotretinoin
7%
Prevalence
21%
Retinoid
16%
Suppurative Hidradenitis
100%
Survival Rate
13%
Survival Time
10%
Wound
16%
Keyphrases
Comorbidity
16%
Disease Burden
16%
Dutch Cohort
16%
Guselkumab
16%
Hidradenitis Suppurativa
33%
Infectiveness
5%
Population-based
16%
Smoking Behavior
16%
Socioeconomic Status
16%
Tool Classification
16%
